Genomic Landscape of Ewing Sarcoma Defines an Aggressive Subtype with Co-Association of <i>STAG2</i> and <i>TP53</i> Mutations

Abstract

Whole-genome sequencing reveals that the somatic mutation rate in Ewing sarcoma is low. Tumors that harbor STAG2 and TP53 mutations have a particularly dismal prognosis with current treatments and require alternative therapies. Novel drugs that target epigenetic regulators may constitute viable therapeutic strategies in a subset of patients with mutations in chromatin modifiers.